Combined Targeting of EGFR and Angiogenesis in Aerodigestive Carcinomas

摘要: The epidermal growth factor receptor (EGFR) and the vascular endothelial (VEGF) are validated molecular targets in aerodigestive carcinomas (ADCs). Effective targeting of these important molecules has been achieved with various strategies—mainly monoclonal antibodies (mAbs) small-molecule tyrosine kinase inhibitors (TKIs). Of particular interest is combined use EGFR VEGF/VEGFR which based on promising early data. Here, we review rationale emerging clinical data this innovative approach. identification validation biomarkers that correlate outcome expected to allow for a more rational inhibitors. Ongoing trials define role patients nonsmall-cell lung cancer (NSCLC) squamous cell carcinoma head neck (SCCHN).